Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7121932 in Multiple Sclerosis
NCT05704361Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Aug 2021
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 1, open-label trial of RO7121932 in multiple sclerosis (MS) (4 arms), sponsored by Roche. Primary endpoints: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), Change From Baseline in Suicide Risk as Assessed Using the Columbia-Suicide Severity Rating Scale and 3 more. Started Aug 2021; status: active, not recruiting.
02
Drugs
RO7121932
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05704361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05704361.